Background: Recently, several case-control studies demonstrated an association between gliptins and bullous pemphigoid (BP) occurrence. However, data on the clinical and immunologic features of gliptin-associated bullous pemphigoid (GABP) are controversial. Objective: This study aimed to clinically and immunologically characterize a large cohort of GABP patients to get an insight into the pathophysiology of this emerging drug-induced variant of BP. Methods: Seventy-four GABP patients were prospectively enrolled and characterized from 9 different Italian dermatology units between 2013 and 2020. Results: Our findings demonstrated the following in the GABP patients: (1) a noninflammatory phenotype, which is characterized by low amounts of circulating and skin-infiltrating eosinophils, is frequently found; (2) immunoglobulin (Ig)G, IgE, and IgA humoral responses to BP180 and BP230 antigens are reduced in frequency and titers compared with those in patients with idiopathic BP; (3) IgG reactivity targets multiple BP180 epitopes other than noncollagenous region 16A. Limitations: A limitation of the study is that the control group did not comprise only type 2 diabetes mellitus patients with BP. Conclusion: GABP patients show peculiar features of anti-BP180 and -BP230 humoral responses, laying the foundation for diagnostic improvements and getting novel insights into understanding the mechanism of BP onset.

Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study / Salemme, A.; Fania, L.; Scarabello, A.; Caproni, M.; Marzano, A. V.; Cozzani, E.; Feliciani, C.; De Simone, C.; Papini, M.; Satta, R. R.; Parodi, A.; Mariotti, F.; Lechiancole, S.; Genovese, G.; Passarelli, F.; Festa, F.; Bellei, B.; Provini, A.; Sordi, D.; Pallotta, S.; Abeni, D.; Mazzanti, C.; Didona, B.; Di Zenzo, G.. - In: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. - ISSN 0190-9622. - 87:1(2022), pp. 56-63. [10.1016/j.jaad.2022.02.036]

Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study

Feliciani C.
Investigation
;
2022-01-01

Abstract

Background: Recently, several case-control studies demonstrated an association between gliptins and bullous pemphigoid (BP) occurrence. However, data on the clinical and immunologic features of gliptin-associated bullous pemphigoid (GABP) are controversial. Objective: This study aimed to clinically and immunologically characterize a large cohort of GABP patients to get an insight into the pathophysiology of this emerging drug-induced variant of BP. Methods: Seventy-four GABP patients were prospectively enrolled and characterized from 9 different Italian dermatology units between 2013 and 2020. Results: Our findings demonstrated the following in the GABP patients: (1) a noninflammatory phenotype, which is characterized by low amounts of circulating and skin-infiltrating eosinophils, is frequently found; (2) immunoglobulin (Ig)G, IgE, and IgA humoral responses to BP180 and BP230 antigens are reduced in frequency and titers compared with those in patients with idiopathic BP; (3) IgG reactivity targets multiple BP180 epitopes other than noncollagenous region 16A. Limitations: A limitation of the study is that the control group did not comprise only type 2 diabetes mellitus patients with BP. Conclusion: GABP patients show peculiar features of anti-BP180 and -BP230 humoral responses, laying the foundation for diagnostic improvements and getting novel insights into understanding the mechanism of BP onset.
2022
Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study / Salemme, A.; Fania, L.; Scarabello, A.; Caproni, M.; Marzano, A. V.; Cozzani, E.; Feliciani, C.; De Simone, C.; Papini, M.; Satta, R. R.; Parodi, A.; Mariotti, F.; Lechiancole, S.; Genovese, G.; Passarelli, F.; Festa, F.; Bellei, B.; Provini, A.; Sordi, D.; Pallotta, S.; Abeni, D.; Mazzanti, C.; Didona, B.; Di Zenzo, G.. - In: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. - ISSN 0190-9622. - 87:1(2022), pp. 56-63. [10.1016/j.jaad.2022.02.036]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2933162
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact